-+ 0.00%
-+ 0.00%
-+ 0.00%

Olema, Bayer partner to test OP-3136 with Nubeqa in metastatic prostate cancer trial

PUBT·05/26/2026 11:02:58
Listen to the news
Olema, Bayer partner to test OP-3136 with Nubeqa in metastatic prostate cancer trial
  • Olema Pharmaceuticals entered a clinical trial collaboration with Bayer to test OP-3136 with Nubeqa (darolutamide) in metastatic castration-resistant prostate cancer.
  • Phase 1b/2 study targets about 36 patients, with initiation expected in H2 2026.
  • Bayer will supply darolutamide; Olema will run the trial, with clinical data and combination-related inventions jointly owned.
  • Olema retains global commercial rights to OP-3136.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260700PRIMZONEFULLFEED9725649) on May 26, 2026, and is solely responsible for the information contained therein.